CSL Behring Announces Positive Reimbursement Decision in Canada for HEMGENIX® (etranacogene dezaparvovec), the First Gene Therapy for Hemophilia

Our Focus on Rare Serious Diseases

Our portfolio of innovative medicines includes a wide range of recombinant and plasma-derived products for treating bleeding disorders, immune deficiencies, and chronic inflammatory demyelinating polyneuropathy, as well as hereditary angioedema and Alpha-1 Antitrypsin Deficiency.